ClinicalTrials.gg
TerminatedNCT05878704Updated Oct 15, 2024

Study of GBT021601 in Participants With Renal Impairment

A Phase 1 interventional study of GBT021601 in Renal Impairment, sponsored by Pfizer. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
Business decision to terminate the trial after the completion of Part 1: Cohort 1 (severe renal impairment). The decision to terminate the trial was not due to any potential safety concerns.

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
34th of 36
8 · median 30
Started
2023
with 1 other
Phase 1
23 of 37
2 open now
Registered
32nd of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2023, is one of 23 in phase 1, and was the 32nd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

Renal Impairment study of GBT021601.

Read the detailed description

This is a Phase 1, two-part, non-randomized, open-label, parallel group study to evaluate the PK, safety, and tolerability of GBT021601 following a single dose administration in adult participants with RI.

03

Conditions studied

  • Renal Impairment

Keywords

  • End stage renal disease
  • Sickle Cell Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, ≥ 18 years of age at the time of Screening.
  • Have liver ( [ALT], aspartate aminotransferase [AST], and total [direct and indirect]) and renal function tests, , and hematocrit values within normal limits or are not at Screening and Day -1 (Cohort 2 only).
  • Has a stable renal function with no clinically significant change in renal status at least 1 month prior to study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Any medical history or abnormal findings upon physical examination, or clinical laboratory tests unrelated to their medical condition related to renal impairment, that might confound the results of the study or pose an additional risk in administering study drug to the participant.
  • Evidence or history of clinically significant allergic (except for untreated, asymptomatic seasonal allergies at the time of study drug administration), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease unrelated to renal impairment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment

    GBT021601

    Drug: GBT021601

Interventions

06

What researchers measure

Primary outcomes

  1. Concentration of GBT021601 in whole blood and plasma

    To evaluate the single-dose whole blood and plasma PK of GBT021601 in participants with renal impairment (RI)

    Time frame: Up to 112 Days

  2. Single-dose PK parameters

    To evaluate the single-dose whole blood and plasma PK of GBT021601 in participants with renal impairment

    Time frame: Up to 112 Days

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs

    To evaluate the safety and tolerability of single dose GBT021601 in participants with renal impairment

    Time frame: Up to 112 Days

  2. Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs

    To evaluate the safety and tolerability of GBT021601 in ESRD participants receiving IHD following a single dose

    Time frame: Up to 112 Days

Other outcomes

  1. Single-dose PK parameters for GBT021601 in RBC

    To evaluate the single-dose RBC PK of GBT021601 in participants with RI

    Time frame: Up to 112 Days

  2. Amount of GBT021601 excreted in urine

    To evaluate the urinary excretion of GBT021601 in participants with RI following a single dose

    Time frame: Up to 112 Days

  3. Descriptive analysis of eGFR versus PK exposure parameters

    The relationship of eGFR, as estimated using serum creatinine and serum cystatin C on GBT021601 PK exposure in participants with RI

    Time frame: Up to 112 Days

  4. Protein binding of GBT021601 in plasma

    To evaluate the protein binding of GBT021601 in participants with RI

    Time frame: Up to 112 Days

  5. Single-dose PK parameters for GBT021601 in RBC

    To evaluate the single-dose RBC PK of GBT021601 in participants with ESRD receiving IHD

    Time frame: Up to 112 Days

  6. Extraction ratio of GBT021601 via dialysis and concentration of GBT021601 in dialysate

    To evaluate the clearance of GBT021601 by IHD in participants with ESRD

    Time frame: Up to 112 Days

07

Study locations

4 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 26, 2023
StartActual
Jun 29, 2023
Primary completionActual
Jul 29, 2024
CompletionActual
Jul 29, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05878704
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jun 29, 2023
Primary completion
Jul 29, 2024
Completion
Jul 29, 2024
Last update
Oct 15, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osivelotor

Start the discussion